194 related articles for article (PubMed ID: 19816242)
1. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection.
Lee K; Yang H; Lim H; Lew HM
Retina; 2009; 29(10):1409-17. PubMed ID: 19816242
[TBL] [Abstract][Full Text] [Related]
2. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension.
Rasier R; Artunay O; Yuzbasioglu E; Sengul A; Bahcecioglu H
Eye (Lond); 2009 Aug; 23(8):1714-8. PubMed ID: 19079149
[TBL] [Abstract][Full Text] [Related]
3. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).
Falkenstein IA; Cheng L; Freeman WR
Retina; 2007 Oct; 27(8):1044-7. PubMed ID: 18040242
[TBL] [Abstract][Full Text] [Related]
4. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
Hollands H; Wong J; Bruen R; Campbell RJ; Sharma S; Gale J
Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
6. Effect of Dorzolamide/Timolol or Brinzolamide/Timolol prophylaxis on intravitreal anti-VEGF injection-induced intraocular hypertension.
Kim GN; Han YS; Chung IY; Seo SW; Park JM; Yoo JM
Semin Ophthalmol; 2013 Mar; 28(2):61-7. PubMed ID: 23448557
[TBL] [Abstract][Full Text] [Related]
7. [Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab].
Wu L; Evans T
Arch Soc Esp Oftalmol; 2010 Nov; 85(11):364-9. PubMed ID: 21277463
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology.
Chung YR; Lee K; Cho EH; Lew HM
Eye (Lond); 2010 Aug; 24(8):1320-4. PubMed ID: 20379211
[TBL] [Abstract][Full Text] [Related]
9. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
10. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
[TBL] [Abstract][Full Text] [Related]
11. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
13. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs.
Carnota-Méndez P; Méndez-Vázquez C; Otero-Villar J; Saavedra-Pazos JA
Eur J Ophthalmol; 2014; 24(5):771-7. PubMed ID: 24706353
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
Pedersen KB; Sjølie AK; Møller F
Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
[TBL] [Abstract][Full Text] [Related]
15. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
Kim JE; Mantravadi AV; Hur EY; Covert DJ
Am J Ophthalmol; 2008 Dec; 146(6):930-4.e1. PubMed ID: 18775528
[TBL] [Abstract][Full Text] [Related]
16. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
17. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
18. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
19. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure.
Kernt M; Neubauer AS; Kampik A
Acta Ophthalmol Scand; 2007 Feb; 85(1):119-20. PubMed ID: 17244226
[No Abstract] [Full Text] [Related]
[Next] [New Search]